immunotherapy

From the Field
Anticipated Cost Savings with Alternate Dosing Schema of Nivolumab/Ipilimumab for the Treatment of Metastatic Melanoma
08/20/2021
Allison Kupsh, PharmD, and colleagues found that the anticipated cost of NIVO3+IPI1 for the treatment of metastatic melanoma may be lower compared when compared with NIVO1+IPI3, amounting to over $1,000,000 in total savings.
Allison Kupsh, PharmD, and colleagues found that the anticipated cost of NIVO3+IPI1 for the treatment of metastatic melanoma may be lower compared when compared with NIVO1+IPI3, amounting to over $1,000,000 in total savings.
Allison Kupsh, PharmD, and...
08/20/2021
Journal of Clinical Pathways
Research in Review
Immunotherapy Better Than Standard of Care for Type of DLBCL
08/03/2017
JCP Editors
Single-agent immunotherapy in patients with a subtype of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) provides more clinical benefit than conventional therapy, according to research published in...
Single-agent immunotherapy in patients with a subtype of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) provides more clinical benefit than conventional therapy, according to research published in...
...
08/03/2017
Journal of Clinical Pathways
Research in Review
Immunotherapy Diminishes Regulatory T-Cells, Improves Outcomes in AML
07/20/2017
JCP Editors
Immunotherapy after complete remission in acute myeloid leukemia (AML) is associated with decreasing levels of regulatory T-cells, which leads to favorable clinical outcomes, according to research published in Cancer...
Immunotherapy after complete remission in acute myeloid leukemia (AML) is associated with decreasing levels of regulatory T-cells, which leads to favorable clinical outcomes, according to research published in Cancer...
...
07/20/2017
Journal of Clinical Pathways
Research in Review
Altered B-Cell Composition May Impact Immunotherapy Effectiveness in AML
07/13/2017
JCP Editors
Initial chemotherapy often alters B-cell composition and immunity in patients with acute myeloid leukemia (AML), which may have implications for the success of further immunotherapy, according to research published...
Initial chemotherapy often alters B-cell composition and immunity in patients with acute myeloid leukemia (AML), which may have implications for the success of further immunotherapy, according to research published...
...
07/13/2017
Journal of Clinical Pathways
Research in Review
Immunotherapy Shows Promise in Rare Type of Lymphoma
07/11/2017
JCP Editors
A recent report demonstrates the promise of programmed death (PD-1) inhibition in improving outcomes for patients with a rare, difficult-to-treat type of lymphoma, published in The New England Journal of Medicine...
A recent report demonstrates the promise of programmed death (PD-1) inhibition in improving outcomes for patients with a rare, difficult-to-treat type of lymphoma, published in The New England Journal of Medicine...
A...
07/11/2017
Journal of Clinical Pathways
Research in Review
PD-1 Inhibitor Improves Response Rates, Survival Times in Certain Patients With NSCLC
06/23/2017
JCP Editors
A programmed death 1 (PD-1) inhibitor is associated with similar efficacy to chemotherapy in patients with non-small cell lung cancer (NSCLC), but improves response rates and survival times in subgroups of patients,...
A programmed death 1 (PD-1) inhibitor is associated with similar efficacy to chemotherapy in patients with non-small cell lung cancer (NSCLC), but improves response rates and survival times in subgroups of patients,...
A...
06/23/2017
Journal of Clinical Pathways
Research in Review
Earlier Endpoint May Be Predictive of Lung Cancer Therapy Outcomes
06/16/2017
JCP Editors
A novel intermediate endpoint could be a useful measure in clinical trials for metastatic non-small cell lung cancer (mNSCLC), according to a recent study published in JAMA (published online June 15, 2017;...
A novel intermediate endpoint could be a useful measure in clinical trials for metastatic non-small cell lung cancer (mNSCLC), according to a recent study published in JAMA (published online June 15, 2017;...
A...
06/16/2017
Journal of Clinical Pathways
Research in Review
PD-L2 Expression May Indicate Response to Immunotherapy in Head and Neck Cancer
06/15/2017
JCP Editors
A recent study suggests that immunotherapies targeting both PD-L1 and PD-L2 may enhance response rates for patients with head and neck squamous cell carcinoma (HNSCC), published in Clinical Cancer Research (published...
A recent study suggests that immunotherapies targeting both PD-L1 and PD-L2 may enhance response rates for patients with head and neck squamous cell carcinoma (HNSCC), published in Clinical Cancer Research (published...
A...
06/15/2017
Journal of Clinical Pathways
Research in Review
Immunotherapy Improves Standard of Care for Multiple Myeloma
06/08/2017
JCP Editors
Adding a targeting agent to standard of care carfilzomib, lenalidomide, and dexamethasone (KRd) for multiple myeloma is a safe and efficacious alternative to autologous stem cell transplantation (ASCT) with KRd,...
Adding a targeting agent to standard of care carfilzomib, lenalidomide, and dexamethasone (KRd) for multiple myeloma is a safe and efficacious alternative to autologous stem cell transplantation (ASCT) with KRd,...
Adding...
06/08/2017
Journal of Clinical Pathways
Research in Review
PD-L1 Testing Uncommon Among NSCLC Patients on Immunotherapy
06/03/2017
JCP Editors
Few patients treated with immunotherapy for metastatic non–small cell lung cancer (NSCLC) at United States community practices receive appropriate programmed death-ligand 1 (PD-L1) expression testing, according to...
Few patients treated with immunotherapy for metastatic non–small cell lung cancer (NSCLC) at United States community practices receive appropriate programmed death-ligand 1 (PD-L1) expression testing, according to...
Few...
06/03/2017
Journal of Clinical Pathways

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use